GASTROINTESTINAL CANCER—COLORECTAL AND ANAL
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY- CRC01.Read more...

Join our subscribers list to get the latest news, updates and special offers directly in your inbox